Tempol the powerful antioxidant

#1

Screenshot 2026-06-19 at 7.22.44 PM
Screenshot 2026-06-19 at 7.22.44 PM958×996 58.1 KB

2 Likes
#2
3 Likes
#3
2 Likes
#4

Tempol: The Antioxidant in the Water Bowl: A Cheap Nitroxide Trims Mortality in Old Mice — But the Controls Died Young**

Japanese researchers report that low-dose tempol, a small-molecule antioxidant added to drinking water, reduced mortality and dampened inflammatory markers in aged mice. The effect is real but modest, and the lifespan claim rests on a control group that appears to have been unusually short-lived.

Aging bodies rust. The slow oxidative damage that accumulates over a lifetime drives a low, smouldering inflammation — sometimes called “inflammaging” — that erodes tissues and immune function. A team at Kyushu University in Japan asked a simple question: if you continuously mop up some of that oxidative damage with a cheap, well-characterised antioxidant, do animals live longer and age better?

Their molecule of choice was tempol, a nitroxide radical that cycles between chemical states and can neutralise several reactive oxygen species. Unlike most dietary antioxidants, which are largely consumed in a single reaction, tempol can be regenerated, acting catalytically. The researchers gave old mice (20–23 months) tempol in their drinking water at a relatively low concentration (6 mM) and compared them to age-matched mice drinking plain water, plus a young reference group.

The headline result: fewer tempol-treated mice died over the 20-month observation window. Critically, this happened without weight loss — distinguishing it from caloric restriction, the most reliable lifespan intervention known. The treated animals also showed lower lipid-peroxidation (a direct readout of oxidative damage), reduced C-reactive protein (an inflammation marker), higher circulating vitamin C, and a partial rescue of the age-related decline in CD4 helper T-cells, a hallmark of the aging immune system.

The “big idea” is that you may not need to starve an organism or hit a specific signalling pathway to nudge lifespan — broadly lowering the oxidative-inflammatory burden might be enough to let old animals reach a more normal endpoint. That positions tempol as a tool for studying the oxidative-stress theory of aging, which has fallen out of fashion as targeted antioxidant trials in humans repeatedly disappointed.

But there is a large asterisk. The study ran only to 20 months — young by the standards of this mouse strain, which can reach roughly 30 months — and reports no median lifespan, no hazard ratio, and an internal contradiction over whether CRP was actually “normalised.” The benefit may reflect rescuing sickly controls from premature death rather than slowing aging itself. It is a promising, inexpensive lead, not a validated longevity drug. [Confidence: High that effects are real and modest; Medium on mechanism; Low that this represents genuine aging modulation]

Actionable insights

The honest take-home for a human biohacker is restraint: this is a mouse study of a research chemical (tempol is not an approved human supplement). What it does offer is conceptual.

Effect-size magnitudes, extracted and calculated:

  • Body temperature rescue: Aged controls dropped from the young value of 38.1°C to 35.9°C; tempol restored this to 36.7°C — recovering about 0.8°C, roughly 36% of the age-related decline. The standardized effect size is large (Cohen’s d ≈ 1.3), though the absolute change is small and its desirability is debatable (lower body temperature is itself associated with longevity under caloric restriction).
  • Mortality: The paper reports “reduced mortality at 20 months” but gives no numbers, so the real-world magnitude cannot be quantified — a serious omission.
  • Metabolic neutrality: No effect on body weight, body fat, glucose, cholesterol, or triglycerides (all effect sizes ≈ 0 for tempol vs aged control). This means it is not working through a caloric-restriction-like mechanism.

The defensible lifestyle lesson is the well-supported one underneath the chemistry: chronic low-grade inflammation and oxidative burden track with biological aging, and the interventions with strong human evidence for lowering them are not exotic — they are exercise, sleep, not smoking, and a polyphenol-rich diet (the paper itself cites resveratrol as producing a comparable CD4 rescue). Tempol itself remains a lab tool. [Confidence: High]

Context

Impact evaluation

The 2024 Journal Impact Factor is 1.7; its CiteScore is 4.8. Using the JIF: The impact score of this journal is 1.7 (JIF; CiteScore 4.8), evaluated against a typical high-end range of 0–60+ for top general science journals, therefore this is a Low impact journal. It is a legitimate, peer-reviewed, Q2 specialty journal in nutrition/free-radical biology — not predatory — but it sits well below the tier where landmark longevity claims are typically published and scrutinised.

#5

A Cheap Antioxidant Mimetic Rewinds Arterial Aging in Mice — But Only While You Keep Taking It

Three weeks of oral TEMPOL, a superoxide dismutase (SOD) mimetic, reversed both flavors of arterial aging in old mice — large-artery stiffening and endothelial dysfunction — by scavenging excess superoxide, restoring nitric oxide signaling, stripping out excess adventitial collagen, and quieting vascular inflammation. The catch: it patches the symptom (excess superoxide) without fixing the broken endogenous defense (MnSOD), implying the benefits are rental, not ownership.

Arteries are arguably the first organ system to betray us as we age, and they do it in two ways: the big elastic arteries (the aorta and its branches) turn stiff like an old garden hose, and the inner lining of smaller conduit arteries loses its ability to relax and widen on demand. Both changes are independent predictors of heart attacks, strokes, and dementia. The leading suspect behind both is oxidative stress — specifically an overproduction of superoxide, a reactive oxygen species that chews up nitric oxide (the molecule that keeps vessels supple) and triggers structural damage and inflammation.

A team at the University of Colorado Boulder asked a clean question: if excess superoxide is the problem, what happens if you simply mop it up? They gave old mice (26 to 28 months, roughly equivalent to humans in their late 70s) three weeks of TEMPOL — a small molecule that mimics the body’s own superoxide-quenching enzyme — dissolved in their drinking water.

The results were unusually tidy for an aging study. Aortic superoxide, measured directly with electron paramagnetic resonance spectroscopy, dropped back to youthful levels. Aortic stiffness, measured as pulse wave velocity, fully normalized. Endothelial function — the arteries’ ability to dilate — was completely restored, and so was the nitric oxide signaling and the eNOS enzyme behind it. Markers of oxidative damage (nitrotyrosine) and the superoxide-generating enzyme NADPH oxidase came back down. Three inflammatory cytokines (IL-1beta, IL-6, TNF-alpha) returned to young levels. The team also showed in cultured cells that scavenging superoxide directly reverses the excess collagen deposition that stiffens the arterial wall.

The “big idea” is that a single upstream lever — superoxide burden — sits beneath structural stiffening, endothelial decline, and inflammation simultaneously. Pull that lever and all three move together. That makes redox scavenging an attractive, mechanistically unified target for vascular aging.

But two details deserve a skeptic’s eye. First, TEMPOL did not restore MnSOD, the mitochondrial antioxidant enzyme that was depleted with age — meaning the drug compensates for, rather than repairs, the underlying deficit. Second, the study lasted three weeks, used only males, measured no survival outcomes, and was small. This is a strong proof-of-mechanism, not a longevity drug ready for humans.

Actionable Insights

TEMPOL is not an established human longevity intervention, and “antioxidant” supplements broadly have repeatedly failed to replicate vascular benefits in human trials. Treat any extrapolation as low confidence.

What the data does support, as effect-size magnitudes:

  • Endothelial function: old mice dilated to ~76% of maximum versus ~95% in young; TEMPOL restored this to ~95%. That is essentially a 100% closure of the age gap (~19 percentage-point recovery), a very large effect (Cohen’s d ~2.7).
  • Arterial stiffness: pulse wave velocity rose ~22% with age (418 → 508 AU) and TEMPOL brought it back to 434, again closing roughly 80 to 100% of the gap (d ~1.4).
  • Inflammation and oxidative markers: age roughly doubled-to-tripled nitrotyrosine and NADPH oxidase; both normalized.

The transferable concept — not a protocol — is that the superoxide/NADPH-oxidase/nitric-oxide axis is a plausibly modifiable node in vascular aging. Established human levers that act on the same axis (aerobic exercise, which this same lab has shown reverses arterial inflammation; and nitric oxide support) are better-evidenced bets than chasing TEMPOL.

Context

Impact Evaluation

Current metrics: Journal Impact Factor 7.1 (2024) and CiteScore 12.4 (2024) for Aging Cell; the 2023 impact factor was 8.0, and it ranks #5 of 50 (Q1) in Geriatrics and Gerontology. ResearchGate + 2

The impact score of this journal is 7.1, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal on the absolute general-science scale. The important caveat: within its own field it is Elite — it is widely regarded as the leading specialist journal in the biology of aging

#6

Safety review, from Claude 4.8:

Preclinical Evidence of Mammalian Safety

The acute toxicity profile of the superoxide dismutase (SOD) mimetic TEMPOL (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) varies strictly based on the route of administration in mammalian models:

  • Oral LD50​ (Rat): 1 g/kg body weight, positioning it as a relatively low-toxicity compound via oral ingestion (Vereshchagin et al., 2022).
  • Intravenous / Intraperitoneal LD50​ (Rodent): ~2 mmol/kg (which converts to approximately 344.5 mg/kgbased on a molecular weight of 172.24 g/mol) (Yang et al., 2016).
  • Maximum Tolerable Dose (MTD): In acute systemic in vivo radioprotection studies using mice, the strict MTD is established at 275 mg/kg (Davis et al., 2011).

TEMPOL is a cell-permeable, stable nitroxide radical that acts catalytically to dismutate superoxide (O2∙−​), facilitate hydrogen peroxide (H2​O2​) metabolism via catalase-like actions, and prevent Fenton-derived hydroxyl radical (∙OH) formation (Wilcox & Pearlman, 2008).

1. Chronic Administration and Lifespan Extension

Preclinical safety is highlighted by rodent longevity models. Continuous administration of TEMPOL in food or drinking water from birth significantly prolonged the lifespan of normal mice without accelerating tumor development (Wilcox, 2010). This underscores its safety profile during long-term, low-dose exposure.

2. Tissue-Specific Tolerability

At sub-lethal therapeutic doses (e.g., 50 mg/kg to 200 mg/kg body weight), TEMPOL is highly tolerated across various mammalian disease models. It demonstrates protective efficacy against ischemia/reperfusion injury, dahl salt-sensitive hypertension, and neuroinflammation (Wilcox & Pearlman, 2008; Yang et al., 2016). At lower ranges (e.g., 50 mg/kg), it upregulates endogenous antioxidant defenses like the PI3K/Akt/Nrf2 pathway (Zhang et al., 2016).

3. Cellular Genotoxicity Profile

In vitro assays confirm that TEMPOL does not alter baseline sister chromatid exchanges (SCEs) or induce spontaneous chromosomal aberrations in human cells at therapeutic concentrations (Sadowska-Bartosz & Bartosz, 2024). Instead, it functions as a antigenotoxic shield against external mutagens like cisplatin or radiation (Sadowska-Bartosz & Bartosz, 2024).

Clinical Status and Literature Distinctions

True clinical trial data for TEMPOL (4-hydroxy-TEMPO) is limited compared to its extensive animal literature. Human clinical safety evidence originates primarily from topical or localized applications rather than systemic ingestion:

  • Topical Radioprotection: Clinical phase I/II trials evaluated topical TEMPOL gel to prevent radiation-induced alopecia in cancer patients. These studies showed favorable local tolerability with minimal systemic absorption or systemic adverse events.
  • Systemic Barriers: Systemic development in humans has historically faced challenges due to transient hemodynamic side effects (such as acute, reversible decreases in blood pressure via reflex vasodilation and central sympathetic inhibition) observed at upper-tier doses in animal models (Wilcox & Pearlman, 2008).

Scholarly Debates & Knowledge Gaps

1. The Paradoxical Pro-Oxidant Shift

A core debate in nutritional and molecular biology centers on TEMPOL’s concentration-dependent biphasic nature. While micromolar concentrations (50–200 μM) are strongly cytoprotective, millimolar concentrations (0.5–4 mM) trigger a pro-oxidant shift. At high concentrations, TEMPOL induces mitochondrial membrane potential loss, depletes intracellular glutathione (GSH), and paradoxically elevates O2∙−​ levels, initiating apoptosis in both malignant and healthy mammalian cells (Park, 2022).

2. Gut Microbiota Disruption

Emerging metabolomic data reveals that oral TEMPOL alters the mammalian gut microbiome structure. It selectively suppresses specific bacterial communities, resulting in a distinct decrease in cecal and fecal short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate. This shifts host metabolism into a more catabolic state. This introduces a complex trade-off between systemic antioxidant status and optimal microbiome-driven metabolic health.

3. Data Gaps Required for Full Validation

To conclusively determine systemic safety thresholds for longevity applications in humans, the field lacks:

  • Long-term Phase III Human Safety Data: Comprehensive data evaluating oral systemic administration over multi-year timelines.
  • Definitive Human Pharmacokinetic (PK) Mapping: Clear tracking of human metabolic conversion rates from the active nitroxide radical to its reduced hydroxylamine form (TEMPOL-H).

References

Davis, R. M., Sowers, A. L., DeGraff, W., Bernardo, M., Thetford, A., Krishna, M. C., & Mitchell, J. B. (2011). A novel nitroxide is an effective brain redox imaging contrast agent and in vivo radioprotector. Free Radical Biology and Medicine, 51(4), 780–790. https://doi.org/10.1016/j.freeradbiomed.2011.05.019

Cited by: 62

Park, W. H. (2022). Tempol inhibits the growth of lung cancer and normal cells through apoptosis accompanied by increased O2•− levels and glutathione depletion. Molecules, 27(21), 7341. https://doi.org/10.3390/molecules27217341

Cited by: 16

Sadowska-Bartosz, I., & Bartosz, G. (2024). The cellular and organismal effects of nitroxides and nitroxide-containing nanoparticles. International Journal of Molecular Sciences, 25(3), 1446. https://doi.org/10.3390/ijms25031446

Cited by: 34

Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R T., Perrone, R. D., Dandurand, A., Ouyang, J., Czerwiec, F. S., & Blais, J. D. (2017). Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology Dialysis Transplantation, 32(7), 1262-1262. https://doi.org/10.1093/ndt/gfx079

Cited by: 195

Vereshchagin, A. A., Kalnin, A. Y., Volkov, A. I., Lukyanov, D. A., & Levin, O. V. (2022). Key features of TEMPO-containing polymers for energy storage and catalytic systems. Energies, 15(7), 2699. https://doi.org/10.3390/en15072699

Cited by: 26

Wilcox, C. S. (2010). Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacology & Therapeutics, 126(1), 119–145. https://doi.org/10.1016/j.pharmthera.2010.01.003

Cited by: 594

Wilcox, C. S., & Pearlman, A. (2008). Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacological Reviews, 60(4), 418–469. https://doi.org/10.1124/pr.108.000240

Cited by: 467

Yang, X., Hondur, G., & Tezel, G. (2016). Antioxidant treatment limits neuroinflammation in experimental glaucoma. Investigative Ophthalmology & Visual Science, 57(6), 2344. https://doi.org/10.1167/iovs.16-19153

Cited by: 94

Zhang, G., Wang, Q., Zhou, Q., Wang, R., Xu, M., Wang, H., Wang, L., Wilcox, C. S., Liu, R., & Lai, E. Y. (2016). Protective effect of tempol on acute kidney injury through PI3K/Akt/Nrf2 signaling pathway. Kidney and Blood Pressure Research, 41(2), 129–138. https://doi.org/10.1159/000443414

#7

Clinical trials for Tempol:

Despite decades of preclinical promise, oral TEMPOL has been tested in remarkably few human studies, and the only one that produced an actual efficacy readout failed. Here is what exists, sorted by how much real data came out of each.

1. COVID-19 — the only oral TEMPOL trial with reported efficacy results (FAILED)

This is the substantive one. Sponsored by Adamis Pharmaceuticals (drug designated MBM-02 / Tempol, originally from Matrix Biomed).

  • Design: Adaptive, randomized, double-blind, placebo-controlled Phase 2/3 trial enrolling roughly 248 unvaccinated participants aged 18+ with early COVID-19 and at least one comorbidity (hypertension, diabetes, obesity, cancer, chronic renal disease, or immunodeficiency). Clinical Trials Arena
  • Dose/route: 800 mg daily, given as two oral 400 mg capsules, for up to 21 days versus placebo. BioSpace
  • Primary endpoint: rate of hospitalization and sustained clinical resolution of symptoms at day 14.
  • Outcome: It failed. The third interim analysis showed Tempol did not reach statistical significance on the primary endpoint of sustained clinical symptom resolution at day 14 versus placebo, and the Data Safety Monitoring Board recommended halting the study early. The DSMB recommended stopping for lack of efficacy but identified no safety concerns in subjects who received Tempol. Clinical Trials ArenaThe Pharmaletter
  • Important caveat from the sponsor: The company suggested that widespread vaccination and the milder Omicron variant during the trial may have obscured any effect, citing a lower-than-expected hospitalization rate of under 1% compared with other COVID-19 treatment trials. That is a post-hoc rationalization, not a positive result. Clinical Trials Arena
  • Links/sources: Adamis press release (GlobeNewswire, Sept 21 2022): Adamis Provides Update on the Phase 2/3 Trial of Tempol in ; trial-fail coverage: https://www.clinicaltrialsarena.com/news/adamis-covid-trial-endpoint/ ; dosing initiation: https://www.clinicaltrialsarena.com/news/adamis-dosing-covid-trial/

Note: results were disclosed via press release/interim analysis, not (as far as I can find) a peer-reviewed publication with full data.

2. Prostate cancer — single-patient expanded access (no outcome data)

  • Registry: NCT04337099, sponsor Matrix Biomed, Inc.
  • Design: A single-patient compassionate-use (expanded access) study of MBM-02 (Tempol) for prostate cancer, with study drug administered orally as a 200 mg capsule, seven days a week, up to a maximum total daily dose of 800 mg for up to 12 months. clinicaltrials
  • Outcome: None published. This is expanded access for one patient, not a controlled trial, so it generates no efficacy or safety dataset of value.
  • Link: ClinicalTrials.gov

3. Head/neck cancer toxicity (cisplatin/radiation) — registered, no results found

  • Registry: NCT03480971.
  • Design: A roughly 10-week trial assessing whether Tempol can prevent or reduce mucositis, nephrotoxicity, and ototoxicity associated with cisplatin and radiation in head and neck cancer patients, with about 120 participants planned. A clinical trial was described as underway to assess Tempol’s ability to reduce toxicity from cisplatin and radiotherapy in head and neck cancer (NCT03480971). ICH GCPResearchGate
  • Outcome: I could not find published results or a confirmed completion status, and I could not definitively verify the route of administration from available sources — TEMPOL for head/neck radiation has historically also been studied as a topical agent, so treat this entry as registered-but-unconfirmed rather than a clean oral-systemic readout.
  • Link: ClinicalTrials.gov

What is not in scope (but worth knowing)

TEMPOL’s most-developed human application has been topical, not oral — a topical gel (MTS-01) studied for radiation-induced alopecia and dermatitis. Those don’t count as oral TEMPOL trials, but they’re the reason TEMPOL has a human safety footprint at all.

Bottom line

For your purposes as a longevity reader: there is no human trial of oral TEMPOL for cardiovascular aging, arterial stiffness, or any aging-related endpoint — the mouse arterial-aging work from the Fleenor/Seals paper you analyzed has never been translated to a human oral trial. The single adequately-powered oral TEMPOL efficacy trial (COVID-19) was negative, though notably it raised no safety signal, which is the one mildly encouraging data point for the molecule’s tolerability. Everything else is single-patient access or unverified.